Millions of people—about one-third of the adult population in the developed world— suffer from hypertension. Despite widespread efforts to better diagnose and manage hypertension, a number of factors, including the complexity of the disease, patient noncompliance with complicated drug regimens, side effects of medications and drug ineffectiveness, have resulted in poor blood pressure control rates. An increase in renal sympathetic nerve activity has been shown to be a significant contributing factor in developing and maintaining hypertensive states. It is becoming clear that the development of new, device-based therapies to perform minimally invasive renal sympathetic denervation — from catheter-based drug delivery systems to sonic and RF ablation devices — can provide a distinct advantage in combating this major healthcare burden.

Since the inception of this novel technology, CBSET has led the way in developing animal models for assessing safety, as well as quantitative methods for assessing and understanding efficacy, including biomarker assays, histomorphometry, and even computational modeling. These have been presented in international conferences and published in peer-reviewed journals, cementing CBSET’s status as a key opinion leader in the evaluation of neuroablation technologies.

Renal Denervation
CBSET has developed specialized expertise in the development and application of minimally invasive device-based interventional therapies for renal denervation.Download flyer